Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000 argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002 it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it.
This page contains content from the copyrighted Wikipedia article "Argatroban"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
